ECM
CBIO

ExodusPoint Capital Management’s Crescent Biopharma CBIO Stock Holding History

ExodusPoint Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-357
Closed -$107K – 1696
2024
Q1 		$107K Sell
357
-601
-63% -$180K ﹤0.01% 1408
2023
Q4 		$226K Buy
+958
New +$149K ﹤0.01% 1254
2022
Q2 		– Sell
-107
Closed -$12K – 2124
2022
Q1 		$12K Sell
107
-186
-63% -$21.8K ﹤0.01% 2114
2021
Q4 		$42K Buy
293
+69
+31% +$12.5K ﹤0.01% 2050
2021
Q3 		$49K Sell
224
-388
-63% -$82.2K ﹤0.01% 1972
2021
Q2 		$142K Buy
612
+441
+258% +$112K ﹤0.01% 2073
2021
Q1 		$52K Sell
171
-380
-69% -$136K ﹤0.01% 2025
2020
Q4 		$207K Buy
+551
New +$193K ﹤0.01% 1714

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return